{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019958","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.327956+00:00","generated_at":"2026-06-01T22:50:44.776125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INVO Bioscience Q1 revenue up 353% to $1.58M, net loss narrows to $1.6M","bullets":["Revenue $1,576,286, up 353% YoY from $348,025; clinic revenue up 417% to $1.54M.","Net loss $(1.6) million vs $(2.6) million; Adjusted EBITDA improved to $(0.5) million from $(1.7) million.","Merger with NAYA Biosciences pending; shareholders to receive 7.3333 INVO shares per NAYA share (~18.15M shares total).","NAYA has provided $906k in Series A Preferred Stock financing towards $5M minimum condition for merger.","Management expects to reach break-even on current operations (ex-merger) in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019958","json":"https://secwatch.observer/filing/0001493152-24-019958.json","markdown":"https://secwatch.observer/filing/0001493152-24-019958.md","text":"https://secwatch.observer/filing/0001493152-24-019958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:50:44.776125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba7f0763cf4a57710abecab024b0c9e777faa5f0","claim":"INVO Fertility, Inc. reported financial results for the first quarter of 2024.","evidence_excerpt":"On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/0001493152-24-019958-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}